Clinical trials: Chloride Disorder
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea
Acute Kidney Injury
Fluid Chloride and AKI in Cardiopulmonary Bypass
Acute kidney injury (AKI) is a potential complication of cardiac surgery. In animal models, excess exogenous Cl- ion in the bloodstream is associated with AKI.
- Trial name
- NCT02668952
- Testing
- 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of New Mexico
Hematologic Disorder
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect…
- Trial name
- NCT01924169
- Testing
- Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Onychomycosis
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus.
- Trial name
- NCT00443820
- Testing
- terbinafine
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 526 people
- Sponsor
- Novartis Pharmaceuticals
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Salvage Ovarian FANG™ Vaccine + Carboplatinum
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with carboplatinum. All patients will have Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking.
- Trial name
- NCT01867086
- Testing
- Vigil™ Vaccine, Carboplatinum, Carboplatinum and Taxol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gradalis, Inc.
Asthma
Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma
The Purpose of this study is to evaluate the safety and efficacy of SK-1211 inhalation challenge in children with bronchial asthma.
- Trial name
- NCT02097537
- Testing
- Methacholine Chloride (SK-1211)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end…
- Trial name
- NCT01040728
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Hemophilia A
Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously…
- Trial name
- NCT02962765
- Where
- 39 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Octapharma
Cystic Fibrosis
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
- Trial name
- NCT02170025
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 21 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01040130
- Testing
- Olodaterol (BI 1744)
- Where
- 19 sites in Australia, Austria and 3 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
The primary objective of this study is to determine the efficacy and safety of 4 doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in patients with asthma in comparison to…
- Trial name
- NCT01013753
- Testing
- Olodaterol (BI 1744) high, Olodaterol (BI 1744) medium, Olodaterol (BI 1744) very low
- Where
- 27 sites in Austria, Germany and 4 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Severe Haemophilia A
Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand…
- Trial name
- NCT01863758
- Testing
- Human-cl rhFVIII
- Where
- 20 sites in Austria, Bulgaria and 6 more
- Volunteers
- 66 people
- Sponsor
- Octapharma
Severe Hemophilia A
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
- Trial name
- NCT01712438
- Testing
- Human cl rhFVIII
- Where
- 37 sites in United States, Belarus and 15 more
- Volunteers
- 110 people
- Sponsor
- Octapharma
Advanced Gynecological Cancers, Ovarian Cancer
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer…
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03073525
- Testing
- Vigil, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gradalis, Inc.
Bacterial Vaginosis, Vaginal Infection
Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis
The goal of this clinical trial is to show the efficacy and safety of dequalinium chloride in the treatment of bacterial vaginosis compared to metronidazole.
- Conditions
- Bacterial Vaginosis, Vaginal Infection, Vaginal Diseases
- Trial name
- NCT05788991
- Testing
- Dequalinium Chloride, Metronidazole Oral
- Where
- 14 sites in Czechia, Poland and 1 more
- Volunteers
- 151 people
- Sponsor
- Medinova AG
Asthma
A Study of 2 Doses of MAP0010 in Asthmatic Children
The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.
- Trial name
- NCT00697697
- Testing
- 0.135mg MAP0010, 0.25mg MAP0010
- Volunteers
- 192 people
- Sponsor
- Allergan
Severe Haemophilia A
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses.
- Trial name
- NCT02256917
- Testing
- Human cl rhFVIII
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 58 people
- Sponsor
- Octapharma
Breast Carcinoma, Ductal Breast Carcinoma In Situ
Oxybutynin Chloride in Managing Hot Flashes
This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy.
- Conditions
- Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02961790
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Academic and Community Cancer Research United
Acute Kidney Injury
Isotonic Solution Administration Logistical Testing
The administration of intravenous crystalloids is ubiquitous in the care of the critically ill. Commonly available crystalloid solutions contain a broad spectrum of electrolyte compositions including a range of chloride…
- Trial name
- SALT (NCT02345486)
- Testing
- 0.9% sodium chloride, Physiologically balanced fluid
- Where
- United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University